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ail address: dm08013e@st.kitasato-u.ac.jp (J.a b s t r a c tIntroduction: The long-term effect of angiotensin II receptor blockers (ARBs) on atrial
ﬁbrillation (AF) is unclear. In this study, we evaluated the change in the ﬁbrillation cycle
length (FCL) in patients under long-term ARB therapy for chronic AF.
Methods and results: The study population consisted of 25 chronic AF patients who were
prescribed the same medication for more than 6 years and in whom speciﬁc ECG
recording for FCL evaluation could be performed before and after the 6-year observation
period. The patients were divided into 2 groups: those with and without ARB (ARB group
and non-ARB group and n¼15 and 10, respectively). FCL was calculated by the spectral
analysis of the ﬁbrillation waves in the surface ECG. There was no signiﬁcant difference in
the clinical characteristics between the 2 groups. In the ARB group, the mean FCL was
prolonged from 154720 ms to 187737 ms (p¼0.005), whereas it remained unchanged
in the non-ARB group (150712 ms vs. 149710 ms). In the comparison between patients
with and those without FCL prolongation (430 ms; n¼6 and 19, respectively), a signiﬁ-
cant difference was observed only in those prescribed ARBs.
Conclusion: In cases of chronic AF, FCL might be prolonged under long-term ARB treatment.
& 2012 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.1. Introduction
Several experimental studies utilizing animal models of
atrial ﬁbrillation (AF) have shown a suppressive effect of
angiotensin II receptor blockers (ARBs) on the process of
atrial remodeling serving as the arrhythmogenic substrate
for AF [1,2]. We have previously reported that olmesartan
suppresses the increase in AF inducibility in a canine AF
model by the suppression of tissue ﬁbrosis and down-
regulation of connexin 43. Even in clinical patients with
AF, several sub-analyses of mega-trials have highlightedrt Rhythm Society. Publish
Kishihara).the potential of using ARBs as upstream therapeutic
agents for the suppression of AF [3–5]. However, recent
prospective clinical trials on ARBs with suppression of AF
as the primary endpoint have failed to document positive
results [6,7]. These results clearly indicate that the sup-
pression of AF using upstream ARB therapy is complicated
and that its effect should be evaluated by a speciﬁc
method of determining whether there is any positive
effect in clinical AF cases.
In the present study, we focused on the long-term
effect (in years) of ARBs on the AF substrate. However,
evaluation of the atrial electrophysiological properties of
clinical patients is technically difﬁcult because an invasive
cardiac electrophysiological study using electrode cathe-
ters cannot be repeated frequently. Instead, we measured
the ﬁbrillation cycle length (FCL) by the spectral analysis
of the ﬁbrillation waves in the surface electrocardiogramed by Elsevier B.V. All rights reserved.
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for evaluating the electrophysiological properties of the
atria [12–16]. Therefore, factors inﬂuencing the atrial
electrophysiological properties, if present, might be
detected by the observation of the FCL. In this study, we
evaluated a change in the ﬁbrillation cycle length (FCL) in
patients with chronic AF under long-term, i.e., 6-year,
ARB therapy, and FCL and clinical data were compared
between patients with and without ARB therapy.
2. Method
2.1. Study population
The study population consisted of 25 patients with
chronic AF. They were retrospectively recruited from 198
consecutive patients with chronic AF who visited the out-
patient clinic of Kitasato University Hospital, between
January and December 2010. The following criteria were
used for patient selection: (1) diagnosis of chronic AF made
6 years back; (2) FCL measurement using spectral analysis
performed 6 years back; (3) prescription unchanged during
the last 6 years; (4) clinical symptomatic level scored as
class 1 or 2 of the New York Heart Association classiﬁcation;
(5) no documented ischemic heart disease, revasculariza-
tion, or cardiac surgery in the previous year; (6) no antiar-
rhythmic drug use; and (7) no history of catheter ablation
therapy. Concomitant control of the ventricular rate with
b-adrenergic receptor antagonists, calcium-channel blockers,
and digitalis was permitted. All patients were prescribed
an optimal dose of warfarin as anticoagulation therapy to
prevent any cardiogenic embolisms. The retrospective
observation period was 6.070.8 years, and speciﬁc surface
12-lead ECG recording for the spectral analysis was per-
formed to evaluate the FCL. All patients underwent trans-
thoracic echocardiography and physical examination before
and after the observation period to exclude serious heart
disease, and the left atrial dimension (LAD) was measured
in the long axis view (Hewlett-Packard, SONOS-5500,
Tokyo, Japan). The index for the change in the LAD during
the follow-up period (DLAD) was calculated by subtracting
the baseline LAD from that obtained at the follow-up. All
study protocols were approved by the permission of the
Ethics Committee of Kitasato University, and written
informed consent was obtained from all patients.
2.2. Analysis of the ﬁbrillation wave
Spectral analysis was performed using data from the
surface ECG recording in lead V1 (customized ECG-recor-
der FDX-6531, Fukuda Denshi, Co. Ltd., Tokyo, Japan),
which was digitally stored ofﬂine on a microcomputer at a
sampling rate of 1 kHz, and the QRS-T complexes were
subtracted using a template-matching algorithm [12].
To minimize the inﬂuence of circadian change in FCL
data, all ECG recordings were performed between 9:00 am
and 12:00 am. Frequency analysis was performed ofﬂine
on the microcomputer (BIMUTUS II, Kissei Comtec Co. Ltd,
Matsumoto, Japan). Frequency analysis of the subtracted
ECG involved 3 steps: (1) band-pass ﬁltering, (2) applica-
tion of the Hamming window, and (3) 4096-point fastFourier transformation. The 50% overlap of adjacent
spectral analyses allowed the use of an average of 20
epochs of analyses within a single 44-s data set [12]. After
spectral analysis, recordings were displayed as power
spectra, which were quantiﬁed by measuring the peak
frequency signal with the maximum magnitude derived
from each epoch. The peak frequency of the spectrum in
the 3–12 Hz range was converted to a cycle length (CL in
ms¼1000/frequency), deﬁned as FCL, and was calculated
as an average of 20 epochs. The reproducibility of the FCL
data was conﬁrmed by repeating the speciﬁc ECG record-
ing for FCL analysis at least twice in each patient [12]. The
index for the change in FCL during the follow-up period
(DFCL) was calculated by subtracting the baseline FCL
from that obtained at the end of the follow-up period.
2.3. Grouping and comparison of the data
First, the 25 patients were divided into 2 groups: those
with and those without ARB therapy, and the FCL and
clinical data were compared between the groups. Second,
the 25 patients were divided into 3 groups by the change
in the FCL during the 6-year observation period (DFCL),
i.e., prolonged, unchanged, or shortened FCL groups, and
the clinical parameters, including ARB prescription, were
compared among the groups. The presence of the change
in FCL was determined by 9DFCL9430 ms, which is
calculated as twice the mean of the standard deviations
of raw FCL data of 20 epochs in each patient.
2.4. Statistical analysis
All values were expressed as the mean7standard
deviation. Statistical analysis was performed using one-
way ANOVA. A P value of less than 0.05 was considered
signiﬁcant.
3. Results
3.1. Clinical characteristics of the study population
The mean age of the study population was 66710 years;
the female: male ratio was 4:21; and none of the patients
had structural heart disease. The medical prescriptions are
outlined in Table 1. Oral anticoagulation therapy using
vitamin K antagonists was administered to all patients. Of
the 25 patients, 22 had comorbid hypertension, and all the 15
patients in the ARB group were prescribed ARB for the
management of hypertension. The incidence of hypertension
as a comorbidity with chronic AF was higher in the ARB
group than in the non-ARB group (100% vs. 70%, p¼0.024).
ARBs used in the ARB groupwere candesartan (4–12mg) in 7
patients, olmesartan (10–20mg) in 3, valsartan (40–80mg)
in 2, losartan (25–50mg) in 2, and termisartan (20mg) in 1.
Five of the 15 patients in the ARB group were prescribed
calcium-channel blockers as additional therapy for hyperten-
sion, but none of the 10 patients in the non-ARB
group received calcium-channel blockers (p¼0.041). Hyper-
tension was treated with b-blockers and/or diuretics in the
remaining patients in the non-ARB group. No difference was
noted in the level of hypertension control between the
Table 1
Clinical characteristics of the patients of the ARB and non-ARB groups.
Total (n¼25) ARB group (n¼15) Non-ARB group (n¼10) p value
Age 6672 6972 6174 0.07
Sex (M:F) 21:4 12:3 9:1 0.51
AF duration (months) 2972 3273 2474 0.07
sBP (mmHg) 12371 12272 12571 0.20
dBP (mmHg) 7471 7272 7671 0.07
Co-morbidity
Hypertension 22 (88%) 15 (100%) 7 (70%) 0.024
Hyperlipidemia 7 (28%) 4 (27%) 3 (30%) 0.86
Diabetes mellitus 2 (8%) 2 (13%) 0 (0%) 0.23
Echocardiographic data
LAD (mm) 4971 5172 4872 0.27
LVEF (%) 6371 6472 6172 0.36
Medication
Calcium-channel blockers 5 (20%) 5 (33%) 0(0%) 0.041
b-blockers 13 (52%) 7 (47%) 6 (60%) 0.51
Diuretics 10 (40%) 8 (53%) 2 (20%) 0.10
Digitalis 11 (44%) 7(47%) 4 (40%) 0.74
Statins 7 (28%) 4 (27%) 3 (30%) 0.86
HR indicates heart rate; sBP, blood pressure; dBP, diastolic blood pressure; LAD, left atrial dimension; LVDd, left
ventricular diastolic dimension; LVDs, left ventricular systolic dimension; LVEF, left ventricular ejection fraction;
MR, mitral regurgitation and ARB , angiotensin II receptor blocker.
Table 2
Hemodynamic and echocardiographic data of the patients of the ARB and non-ARB groups.












Heart rate (bpm) 7073 7273 0.55 7772 7773 1.00 0.06 0.24
sBP (mmHg) 12272 11772 0.15 12571 11973 0.08 0.23 0.54
dBP (mmHg) 7272 6872 0.21 7671 7473 0.50 0.07 0.11
BNP (pg/mL) 101720 113721 0.68 100717 110 72 9 0.75 0.95 0.93
Echocardiographic data
LAD (mm) 5172 5372 0.29 4872 5074 0.51 0.27 0.44
LVDd (mm) 5271 5072 0.21 5072 4972 0.74 0.40 0.85
LVDs (mm) 3271 3071 0.42 3672 3372 0.31 0.09 0.29
LVEF (%) 6472 6572 0.53 6273 6771 0.07 0.36 0.51
Grade of MR (0:I:II:III:IV) 2:3:7:3:0 2:4:8:2:0 0.53 2:2:6:0:0 1:3:6:0:0 0.78 0.27 0.85
sBP, systolic blood pressure; dBP, diastolic blood pressure; LVDd, left ventricular diastolic dimension; LVDs, left ventricular systolic dimension; MR,
mitral regurgitation.
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The other parameters, including transthoracic echocardio-
graphic data, did not show signiﬁcant differences between
the ARB and non-ARB groups. Table 2 summarizes the
hemodynamic and echocardiographic data of the patients
in the ARB and non-ARB groups. Signiﬁcant differences were
absent between the 2 groups before and after the observation
period.
3.2. Analysis of the ﬁbrillation waves and FCL
Fig. 1 shows a representative example of the results of
spectral analysis of the ﬁbrillation waves. The 2 panels
show frequency powers of 20 consecutive epochs inthe same patients before and after the 6-year follow-up
period. In the provided example, the mean of the peak
frequency powers was 6.67 Hz, and FCL was calculated as
150 ms at the baseline analysis; the respective values
were 5.71 Hz and 175 ms in the analysis at the end of the
follow-up period.
Fig. 2 shows the FCL data of the 2 groups. In the graph,
each thin line indicates FCL data obtained for each patient
before and after the follow-up period, and the means and
zones of standard deviations are shown on both sides of
these lines. At baseline analysis, there was no difference in
the FCL data between the 2 groups (p¼0.62). With regard
to FCL data before and after follow-up, the ARB group
exhibited signiﬁcant prolongation (p¼0.005), whereas the
Fig. 1. An example of spectral analysis of the ﬁbrillation waves in a surface ECG. A representative example of the results of spectral analysis of the ﬁbrillation
waves. The 2 panels show frequency powers of 40 consecutive epochs in the same patients before and after the 6 year follow-up period. The horizontal axis
indicates the frequency and each trace indicates the power spectrum of the ﬁbrillation wave in each 4-s window. Time-series spectral analysis of the ﬁbrillation
waves are shown by 3-dimensional plots of the power spectra during a 41-s period. In this example, the mean of the peak frequency powers was 6.67 Hz and FCL
was calculated as 150ms at baseline analysis; these values were 5.71 Hz and 175ms in analysis at the end of the follow-up period.
Fig. 2. FCL data of the 2 groups. This ﬁgure displays FCL data of the 2 groups. In the graph, each thin line indicates FCL data of each patient before and
after the follow-up period, and the means and zones of standard deviations are shown on both sides of these lines. At baseline analysis, there was no
difference in FCL data between the 2 groups (p¼0.62). With regard to FCL data before and after follow-up, the ARB group exhibited signiﬁcant
prolongation (p¼0.005) whereas the non-ARB group exhibited no difference (p¼0.63). At analysis after follow-up, FCL was longer in the ARB group than
in the non-ARB group (p¼0.005).
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end of the follow-up period, the FCL was longer in the ARB
group than in the non-ARB group (p¼0.005).
3.3. Relationship between FCL and transthoracic
echocardiographic data
As shown in Table 2, transthoracic echocardiographic
data did not exhibit any differences between the 2 groups
or before and after the observation period. Fig. 3 showsthe relationship between DLAD and DFCL during the
6-year follow-up period. No signiﬁcant relationship was
noted between the 2 parameters even between the ARB
sub-groups and the non-ARB group.
3.4. Comparison of patients with and without
changes in FCL
Among the 25 patients, 6, 19, and no patients exhib-
ited prolonged, unchanged, and shortened FCL at the end
Fig. 3. The relationship between DLAD and DFCL. This ﬁgure displays the relationship between DLAD and DFCL during the 6-year follow-up period. There
was no signiﬁcant relationship between the 2 parameters, even among the ARB sub-groups and the non-ARB group.
Table 3
Clinical parameters of the patients of the FCL prolonged and unchanged groups.
Total (n¼25) FCL prolonged
group (n¼6)
FCL unchanged
group (n¼19) p value
Age 6672 6973 6572 0.07
Sex (M:F) 21:04 5:01 16:03 0.96
AF duration (months) 2972 2974 2973 0.97
HR (bpm) 7272 6974 7372 0.31
sBP (mmHg) 12371 12372 12372 0.84
dBP (mmHg) 7471 7271 7472 0.45
BNP (pg/mL) 101713 88717 105717 0.57
Co-morbidity
Hypertension 22 (88%) 6 (100%) 16 (84%) 0.3
Hyperlipidemia 7 (28%) 2 (33%) 5 (26%) 0.74
Diabetes mellitus 2 (8%) 1 (17%) 1 (5%) 0.37
Echocardiographic data
LAD (mm) 4971 5172 4872 0.27
LVDd (mm) 5171 5371 5171 0.43
LVDs (mm) 3371 3172 3472 0.32
LVEF (%) 6371 6572 6272 0.52
Grade of MR (0:I:II:III:IV) 4:5:13:3:0 1:2:2:1:0 1:4:12:2:0 0.59
Medication
ARB 15 (60%) 6 (100%) 9 (47%) 0.02
Calcium-channel blockers 5 (20%) 2 (33%) 3 (16%) 0.35
b-blockers 13 (52%) 3 (50%) 10 (53%) 0.91
Diuretics 10 (40%) 2 (33%) 8 (42%) 0.7
Digitalis 11 (44%) 3 (50%) 8 (42%) 0.73
Statins 7 (28%) 2 (33%) 5 (26%) 0.74
HR, heart rate; sBP, blood pressure; dBP, diastolic blood pressure; LAD, left atrial dimension; LVDd, left ventricular
diastolic dimension; LVDs, left ventricular systolic dimension; LVEF, left ventricular ejection fraction; MR, mitral
regurgitation and ARB, angiotensin II receptor blocker.
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compares the clinical parameters among these groups. As
shown, ARB prescription was the only parameter that
differed signiﬁcantly among the groups.
4. Discussion
The present evaluation of DFCL in chronic AF patients
over a long-term observation period revealed a fewinteresting ﬁndings. First, at the end of the 6-year obser-
vation period, the mean FCL had prolonged from
154720 ms to 187737 ms in patients with ARB therapy
(p¼0.005), but remained unchanged (150712 ms vs.
149710 ms, NS) in patients without ARB therapy. To the
best of our knowledge, this is the ﬁrst study on the change
in FCL data over a long-term observation period, during
which the patients received the same medical therapy.
Furthermore, the prescription of ARB was the only
J. Kishihara et al. / Journal of Arrhythmia 28 (2012) 34–40 39parameter that differed signiﬁcantly between the patients
with and without FCL prolongation. Differences in the
clinical background of the patients, such as age or comor-
bidity, did not contribute to FCL prolongation in this study,
but this lack of inﬂuence may be attributable to the small
study population and therefore warrants further reevalua-
tion in a larger study population.
4.1. Atrial remodeling and FCL shortening in chronic AF
Several studies have demonstrated that the persis-
tence of AF would cause shortening of FCL, indicating
the shortening of atrial refractoriness due to the progres-
sion of atrial electrical remodeling [17,18]. Several meth-
odologies have been proposed for evaluating FCL or atrial
refractoriness, but direct measurement utilizing a cathe-
ter technique would not be feasible for long-term repeti-
tive evaluation. Several reports have documented that
spectral analysis of the ﬁbrillation waves in the surface
ECG recorded in AF patients would be useful for evaluat-
ing FCL [19–21], and this method should be useful for
monitoring the change in FCL or atrial refractoriness in
the same patients repeatedly and non-invasively. Using
this method, Neuberger et al. showed progressive short-
ening of FCL in a relatively early phase of persistent AF
[17]. Sasaki et al. [19] have reported that this shortening
in FCL had a nadir in patients with chronic AF, and it was
reported to be around 150–160 ms. It is unclear whether
the patients in the present study have shown such nadir
of FCL shortening at the baseline evaluation, but because
the mean FCLs were 154720 ms and 150712 ms in the
ARB and non-ARB groups, respectively, their FCLs seemed
to be close to their nadir even at the baseline observation.
4.2. Change in FCL and action of ARBs
FCL can be affected by the action of cardioactive medica-
tion, especially antiarrhythmic agents. Fujiki et al. reported
that class I antiarrhythmic agents result in the prolongation
of the FCL immediately before the interruption of AF [15].
Niwano et al. reported that FCL could also be prolonged by
the action of pilsicainide or bepridil, even in patients with
chronic persistent AF [22]. The precise mechanism of this
change in FCL is unclear because FCL is determined not only
by atrial refractoriness alone but also by the complexity of
plural and random reentries. It is possible that the organiza-
tion or simpliﬁcation of plural reentry circuits of AF results
in the prolongation of FCL, which can be achieved by
the action of class I or III antiarrhythmic agents [23]. In
the present study, FCL in the non-ARB group remained
unchanged, but it was prolonged in the ARB group at the
end of the observation period. Although several experimen-
tal studies have shown that ARB would prevent the short-
ening of atrial refractoriness in the very early phase of
atrial electrical remodeling [1,24,25], the effect of ARBs on
atrial refractoriness in chronic AF has not been reported. In
contrast, several experimental and clinical studies have
documented a decrease in cardiac tissue ﬁbrosis by the
use of ARBs or angiotensin-converting enzyme inhibitors
[26–29]. Because it has been documented that ARBs and
angiotensin-converting enzyme inhibitors exert a ‘‘reverseremodeling’’ effect on the structurally remodeled ventricle
or atrium in patients with heart failure, reverse atrial
structural remodeling might possibly explain the prolonga-
tion of FCL in the present study [30,31]. However, there was
no correlation between DLAD and DFCL, and therefore, the
change in FCL could not be explained by the change in the
atrial dimension, at least in this study. In contrast, the
improvement of atrial ﬁbrosis might be another possible
explanation for FCL prolongation. We can speculate that the
decrease in intercellular ﬁbrosis may improve electrical
intercellular connections and result in an increase in con-
duction velocity and prolongation of the wavelength. These
changes will lead to fusion of smaller reentrant circuits and
may result in the organization of the reentrant circuits
and prolongation of FCL. The actual structural and electro-
physiological changes in the atrial tissues in the ARB
group are unknown, but if long-term ARB therapy could
induce the decrease in atrial ﬁbrosis, i.e., at least a part of
‘‘reverse remodeling’’, the FCL prolongation might be partly
explained, albeit at a high degree of speculation. Conversely,
the mechanism of unchanged FCL in the non-ARB group is
also unclear, but this might be explained by the nadir of FCL
shortening [19].
4.3. Limitations
This study has several limitations. First, although this
study has led to some signiﬁcant conclusions, the number
of patients was limited and the study population may
have some selection bias. Second, mainly because of the
study design, interpolating data from the 6-year period
are missing. Finally, data on various electrophysiological
and structural parameters, such as the atrial refractory
period, atrial conduction velocity, and atrial tissue ﬁbro-
sis, were not available because invasive evaluation
was not included in this study. These points should be
resolved in a prospectively designed study with a larger
study population.
5. Conclusion
Long-term (over 6 years) evaluation of FCL data was
performed in patients with chronic AF, and prolongation
in FCL was observed in some patients. A comparison of
the clinical data suggested that ARB prescription might
be considered as, at least, a causative factor of the FCL
prolongation.
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